Arjo AB (FRA:A39) Total Equity: €725.4 Mil (As of Mar. 2026)


FRA:A39 Arjo AB FRA:A39
73 GF Score
Price €2.37
GF Value €3.27
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Arjo AB Total Equity?

Arjo AB FRA:A39 +6.46% 73 Total Equity is €725.4 Mil as of Mar. 2026. GuruFocus rates FRA:A39 with a GF Score™ of 73/100 and a GF Value™ of €3.27 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Arjo AB's total equity for the quarter that ended in Mar. 2026 was €725.4 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Arjo AB Total Equity Historical Data

* Premium members only.

The historical data trend for Arjo AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arjo AB Total Equity Chart

Arjo AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 653.70 676.03 677.81 724.88 685.24

Arjo AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 715.51 684.29 683.49 685.24 725.44
FRA:A39
73GF Score
Arjo AB FRA:A39
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arjo AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Arjo AB's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1376.269-691.029
=685.2

Arjo AB's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=1436.87-711.426
=725.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €725.4 Mil mean?
Arjo AB (FRA:A39) has a Total Equity of €725.4 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Arjo AB and its competitors.
Is Arjo AB's Total Equity too high?
Arjo AB's current Total Equity is €725.4 Mil. Overall, Arjo AB has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arjo AB's Total Equity compare to MCK and CAH?
Arjo AB's Total Equity of €725.4 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Distribution company?
A good Total Equity depends on the Medical Distribution industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Arjo AB and its competitors. Arjo AB's current Total Equity is €725.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arjo AB stock overvalued right now?
Based on GuruFocus' analysis, Arjo AB (FRA:A39) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.27, compared to a current price of €2.37 — trading 27.4% below its estimated fair value. The current Total Equity is €725.4 Mil. Arjo AB's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Arjo AB (FRA:A39), the current Total Equity is €725.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arjo AB (FRA:A39) Overvalued in 2026?

Based on GuruFocus' analysis, Arjo AB stock appears to be undervalued. The current stock price of €2.37 is trading 27.4% below its estimated GF Value™ of €3.27. GuruFocus considers Arjo AB to be Modestly Undervalued.

Key valuation signals for FRA:A39:

  • Total Equity: €725.4 Mil
  • GF Value™: €3.27 vs. price of €2.37 (27.4% below fair value)
  • GF Score™: 73/100 with 5 warning signs

No single metric tells the full story. See the FRA:A39 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arjo AB Business Description

Address Hans Michelsensgatan 10, Box 48, Malmo, SWE, SE-201 20
Arjo AB is a supplier of medical devices, services, and solutions in Sweden. It serves its services to private and public institutions with acute care and long-term care. The company's offering includes products and solutions for patient handling, hygiene, disinfection, medical beds, therapeutic surfaces, venous thromboembolism (VTE) prevention and diagnostics. The company includes segments: Global Sales, North America, Diagnostics.
73GF Score

Get the complete analysis for FRA:A39

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.37
Price
€3.27
GF Value